Fintel reports that on December 22, 2025, Canaccord Genuity maintained coverage of Tempus AI (NasdaqGS:TEM) with a Buy recommendation. Analyst Price Forecast Suggests 40.19% Upside As of December 21, ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the best healthcare AI stocks to buy now. On December 15, JPMorgan lowered its price ...

The Jefferson Police Department will join Immigration and Customs Enforcement’s “task force model” through an agreement ...

Tempus AI is rated a strong buy for risk-tolerant investors, leveraging its vast proprietary healthcare data to drive ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS exemplifies a public-market growth company where ...

Fintel reports that on December 15, 2025, JP Morgan maintained coverage of Tempus AI (NasdaqGS:TEM) with a Neutral ...

Luxury jeweler Diamond Wish held its grand opening ceremony at The Shops on El Paseo on Nov. 6, celebrating with Champagne, ...

Tempus AI TEM is transitioning from a heavy-investment growth stage toward improved operating leverage and a more scalable mix of revenue. This is possible as the company integrates genomics ...

Last week, Tempus AI Inc. TEM reported its third-quarter 2025 results. Both earnings and revenues beat their respective consensus estimate. Tempus, a technology company leading the adoption of ...

Tempus AI (TEM) delivered 90% revenue growth in Q2 to $314.6M, driven by 115% genomics growth and 36% Data and Insights expansion. Tempus raised full-year 2025 revenue guidance to $1.26B and ...